Webinar

An innovative platform, called AstroPath, has been developed to analyze large multiplex immunofluorescence (mIF) datasets using celestial object–mapping algorithms to rapidly identify optimized predictive phenotypic signatures. In this webinar, Dr. Janis Taube and Dr. Alexander S. Szalay from Johns Hopkins describe how the AstroPath technology was conceived and developed, share successes applying AstroPath to answering questions about tumor microenvironment-immune system interactions, and provide preliminary results of comparisons across different institutions to assess mIF assay performance.

Coronavirus disease 2019 (COVID-19) is a new pandemic disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A multi-institutional exploratory research taskforce, named EXPLORE COVID-19, conducted a longitudinal analysis of immune responses of patients at various stages of COVID-19 severity. The goal of the study, which also included a team from Innate Pharma, was to gain translational insights to better understand the immune response in COVID-19 patients and identify potential targets to fight the viral infection. During this webinar, Dr. Remark will provide an overview of the study methodology. Thereafter, he will focus on the C5a-C5aR1 axis and explain its role in the pathophysiology of acute respiratory distress syndrome. This was done by using several techniques, including multiplexed immunohistochemistry. Together, the data support C5a-C5aR1 axis blockade as a means of limiting myeloid cell infiltration in damaged organs and preventing the excessive lung inflammation and endothelialitis in COVID-19 patients. The results from this study were applied to an ongoing COVID-19 clinical trial.

Marquee webinar featuring the recent neuroscience work, published in Cell, by Dr. Ke-qi Fan, Research Lead, Jin Jin Molecular Immunology Lab, Life Sciences Institute of Zhejiang University

Rakuten Medical Inc. Principal Scientist, Chung-Wein Lee, PhD, describes the workflow outlined in his recently published manuscript in the Journal of Immunological Methods. Dr. Lee explains how his team used Akoya’s multispectral imaging platform and Opal staining kits to reliably interrogate the tumor microenvironment in large B-cell lymphoma, something that was previously a challenge.

NeoGenomics lead scientist for PhenoImager™ HT (formerly Vectra® Polaris™) studies, Sara Pollan, PhD, explains the process to successfully optimize and validate a custom 7-color opal panel for multiplex immunofluorescence using the PhenoImager HT platform, to successfully profile and quantify exhausted T-cells in head and neck squamous cell carcinoma.